Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind it. The agreement – which ...

Sandoz's Erelzi has become the first biosimilar of Amgen's Enbrel (etanercept) blockbuster inflammatory diseases drug to gain FDA approval. Erelzi (etanercept-szzs) has been approved in all uses ...

The statements below are extracted from the Company's annual report for the year ended 31 March 2025 (the Annual Report). The Annual Report, which includes the notice of the Company's forthcoming ...